

CONTENTS

Preface	v
Contributors	xi

Part I Genomic Experimental Approaches in Oncology

1 Toward the Realization of the Promise of Microarrays in Oncology	3
<i>Natalie Stickle and Neil Winegarden</i>	
2 Cell-Based Models to Identify Genetic Variants Contributing to Anticancer Drug Response	19
<i>M. Eileen Dolan and Howard McLeod</i>	
3 Proteomic Analysis in Cancer Patients	33
<i>Yasuhiro Kuramitsu and Kazuyuki Nakamura</i>	
4 MicroRNAs and Discovery of New Targets	47
<i>Soken Tsuchiya, Yasushi Okuno, and Gozoh Tsujimoto</i>	
5 Pharmacogenomics of the National Cancer Institute's 60-Tumor Cell Panel	57
<i>Anders Wallqvist, Ruili Huang, and David G. Covell</i>	
6 Use of Single-Nucleotide Polymorphism Array for Tumor Aberrations in Gene Copy Numbers	75
<i>Kwong-Kwok Wong</i>	

Part II Pharmacogenomics of Toxicity and Response Of Chemotherapy

7 Concordance Between Tumor and Germline DNA	91
<i>Sharon Marsh</i>	

-
- 8 Epidermal Growth Factor Receptor Mutations and Sensitivity to Selective Kinase Inhibitors in Human Lung Cancer 103
Anurag Singh, Sreenath V. Sharma, and Jeffrey Settleman
- 9 BCR-ABL Mutations and Imatinib Resistance in Chronic Myeloid Leukemia Patients 127
Mark R. Litzow
- 10 Role of Thymidylate Synthase Gene Variations in Colorectal Cancer Patients 151
Georg Lurje and Heinz-Josef Lenz
- 11 Thiopurines in the Treatment of Childhood Acute Lymphoblastic Leukemia and Genetic Variants of the Thiopurine S-Methyltransferase Gene 173
Martin Stanulla, Elke Schaeffeler and Matthias Schwab
- 12 Impact of Polymorphisms on the Clinical Outcomes of Monoclonal Antibody Therapy Against Hematologic Malignancies 203
Dong Hwan Kim
- 13 DNA Repair and Mitotic Checkpoint Genes as Potential Predictors of Chemotherapy Response in Non-Small-Cell Lung Cancer 231
Rafael Rosell, Miquel Taron, Mariacarmela Santarpia, Fernanda Salazar, Jose Luis Ramirez, and Miguel Angel Molina
- 14 Dihydropyrimidine Dehydrogenase (Dpyd) Gene Polymorphism: Portrait of a Serial Killer 249
Joseph Ciccolini, Cédric Mercier, and Gérard Milano
- 15 Impact of UDP-Glucuronosyltransferase 1A Haplotypes on Irinotecan Treatment 267
Kimie Sai, Hironobu Minami, Yoshiro Saito, and Jun-ichi Sawada
- 16 Microarray Profiling in Breast Cancer Patients 287
Yong Qian, Xianglin Shi, Vincent Castranova, and Nancy L. Guo
- 17 Role of the Folate-Pathway and the Thymidylate Synthase Genes in Pediatric Acute Lymphoblastic Leukemia Treatment Response 299
Lea Cunningham and Richard Aplenc

Part III Pharmacogenomics in Clinical Drug Development in Oncology

18	Pharmacogenomics in Drug Development: A Pharmaceutical Industry Perspective	313
	<i>Tal Zaks</i>	
19	Identification of Pharmacogenomic Biomarker Classifiers in Cancer Drug Development	327
	<i>Richard Simon</i>	
20	Toxicogenomics Application to Oncology Drug Development	339
	<i>Luigi Calzolari and Teresa Lettieri</i>	
21	Strategies to Identify Pharmacogenomic Biomarkers: Candidate Gene, Pathway-Based, and Genome-Wide Approaches	353
	<i>Xifeng Wu, Jian Gu, and Margaret R. Spitz</i>	
	Index	371